- BridgeBio adds $1B as it prepares three more drug launchesBridgeBio Pharma has reloaded with about $1 billion in a preferred equity deal to bolster its reserves ahead of three potential drug launches over the next year. The California biotech, which for…Endpoints · 26d ago↗ source
- 92Bio revives a T cell engager it had transferred to AmgenA small California startup is reviving an experimental T cell engager that its scientists originally developed but had handed off to Amgen years ago. After repeatedly saying it would bring the drug…Endpoints · 26d ago↗ source
- Angitia ends Phase 3 in disc disease; Abivax targets $800M on colitis data🩻 Angitia Biopharmaceuticals drops Phase 3: The US and China biotech terminated a late-stage trial of AGA111 in patients with degenerative disc disease who had a lumbar interbody fusion, according…